PACIFIC BIOSCIENCES OF CALIF (PACB) Stock Analyst Ratings
USA - NASDAQ:PACB - US69404D1081 - Common Stock
1.78 USD
-0.13 (-7.05%)
1.78 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 75% to PACB. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 2.08. This target is 16.76% above the current price.
PACB was analyzed by 17 analysts. The buy percentage consensus is at 75. So analysts seem to be have mildly positive about PACB.
In the previous month the buy percentage consensus was at a similar level.
PACB was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-11 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-06-25 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-15 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-05-15 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-04-10 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-03-25 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-02-20 | Piper Sandler | Reiterate | Neutral -> Neutral |
| 2025-02-18 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-02-18 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-02-14 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-01-23 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-11-11 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2024-11-11 | UBS | Downgrade | Buy -> Neutral |
| 2024-11-11 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-08-28 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2024-08-12 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-08-08 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-08 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-06-03 | Jefferies | Initiate | Buy |
| 2024-05-15 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-05-13 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-05-10 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2024-04-22 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2024-04-19 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-04-18 | Bernstein | Maintains | Outperform -> Outperform |
| 2024-04-18 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2024-04-18 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2024-04-17 | TD Cowen | Maintains | Buy -> Buy |
| 2024-04-10 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2024-04-10 | Goldman Sachs | Maintains | Buy -> Buy |
PACIFIC BIOSCIENCES OF CALIF / PACB FAQ
What is the average price target for PACIFIC BIOSCIENCES OF CALIF (PACB) stock?
17 analysts have analysed PACB and the average price target is 2.08 USD. This implies a price increase of 16.76% is expected in the next year compared to the current price of 1.78.
Can you provide the consensus rating for PACIFIC BIOSCIENCES OF CALIF stock?
The consensus rating for PACIFIC BIOSCIENCES OF CALIF (PACB) is 75.2941 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed PACIFIC BIOSCIENCES OF CALIF (PACB)?
The number of analysts covering PACIFIC BIOSCIENCES OF CALIF (PACB) is 17.